Bank of America
KPTI icon

Bank of America’s Karyopharm Therapeutics KPTI Stock Holding History

Bank of America’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-247
Closed -$71K – 6973
2020
Q1 		$71K Sell
247
-2,000
-89% -$552K ﹤0.01% 5705
2019
Q4 		$646K Buy
+2,247
New +$487K ﹤0.01% 4824

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Bank of America's KPTI Position: Q1 2026 in Review

Bank of America reduced its Karyopharm Therapeutics (KPTI) stake by 60% in Q1 2026, selling an estimated $218K and leaving 19,472 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #5506.

Bank of America first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $8.39M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Bank of America held 19,472 shares of Karyopharm Therapeutics worth $108K as of Q1 2026.
  • Bank of America sold 28,616 Karyopharm Therapeutics shares in Q1 2026, an estimated $218K.
  • Karyopharm Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5506 holding.
  • Bank of America first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Bank of America's Karyopharm Therapeutics position peaked at $8.39M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.